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The prediction of arrhythmia recurrences after catheter ablation of atrial fibrillation (AF) remains 
challenging. the aim of current analysis was to investigate the time-dependent prediction of arrhythmia 
recurrences after AF catheter ablation during long-term follow-up. The study included 879 patients 
(61 ± 10 years; 64% males; 39% persistent AF) undergoing first AF catheter ablation. Rhythm outcomes 
were documented using 7-days Holter monitoring. The APPLE score (Age, Persistent AF, imPaired 
eGFR, Left atrium (LA), EF) was calculated at baseline, while MB-LATER score (Male gender, Bundle 
branch block, LA, AF Type, Early Recurrences) 3 months after ablation. The median follow-up time was 
37 months [95%CI 35;39]. ERAF and LRAF occurred in 45% and 64%, respectively. On multivariable 
analysis, ERAF (HR 2.095, 95%CI 1.762–2.490, p < 0.001) was strongly associated with LRAF. The 
APPLE (HR 1.385, 95%CI 1.276–1.505, p < 0.001) and MB-LATER (HR 1.326, 95%CI 1.239–1.419, 
p < 0.001) scores significantly predicted LRAF during follow-up. On the ROC analysis, APPLE (AUC 
0.640, 95%CI 0.602–0.677, p < 0.001) and MB-LATER (AUC 0.654, 95%CI 0.616–0.691, p < 0.001) 
demonstrated moderate prediction. Summarizing, ERAF was the strongest predictor for LRAF in time-
dependent manner. The APPLE and MB-LATER scores demonstrated moderate prediction of arrhythmia 
recurrences during long term follow-up.
Catheter ablation targeting the pulmonary veins still remains the most important therapeutic strategy in atrial 
fibrillation (AF) treatment with continuous escalation of its popularity since the late 1990s1,2. In most patients 
catheter ablation is superior to antiarrhythmic drugs, however, up to 30–50% of ablated AF patients suffer recur-
rences within the first year3. AF recurrences are associated with impaired quality of life and relate to increased 
morbidity and mortality because of relevant cardio- and cerebrovascular events1,4. Also, recurrences lead to 
repeated ablation procedures and higher hospitalization rates and treatment costs5. All this explains a consider-
able clinical interest to predict the risk for recurrences already before invasive procedure with the goal to shape 
personalized strategies in AF patients.
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There have been multiple studies analysing the impact of different scores on recurrence prediction – from the 
CHADS2 and CHA2DS2-VASc scores (designed for the thromboembolic risk prediction) to the specific rhythm 
outcomes prediction scores as ALARMEC, BASE-AF2, CAAP-AF, ATLAS and LAGO6–13.
The APPLE score was originally developed to predict AF recurrences within the first year after catheter abla-
tion14. In contrast, the MB-LATER score has been introduced to predict very late arrhythmia recurrences in 
arrhythmia-free patients within first 12 months after ablation15. Recently, the predictive ability of APPLE and 
MB-LATER scores had been proven to predict electro-anatomical substrate indicating advanced disease stage 
and explaining poor ablation success in such patients16. However, the time-dependent prediction of arrhythmia 
recurrences during very long follow-up period using clinical variables, in addition to APPLE and MB-LATER 
scores have not been studied and was the aim of current analysis.
Methods
study population. The study population consisted of 879 patients from The Leipzig Heart Center AF 
Ablation Registry, which included consecutive high-symptomatic patients presenting for the catheter ablation 
between January 2007 and December 201114. The study was approved by the local Ethical Committee (Medical 
Faculty, University Leipzig) and performed according to the Declaration of Helsinki and Institutional Guidelines. 
All patients provided written informed consent for participation.
Paroxysmal and persistent AF was defined according to current guidelines5. Paroxysmal AF was defined as 
self-terminating within first 48 hours and up to 7 days after onset documented by previous routine electrocardi-
ograms (ECG) or Holter ECG. Persistent AF was defined as any AF episode either lasting longer than 7 days or 
requiring drug or direct current cardioversion for termination. In all patients, transthoracic and transesophageal 
echocardiography was performed prior to ablation. All class I or III antiarrhythmic medications with the excep-
tion of amiodarone were discontinued at least 5 half-lives before the procedure.
The APPLE (one point for Age >65 years, Persistent AF, imPaired eGFR <60 ml/min/1.73 m2, Left atrial (LA) 
diameter ≥43 mm, EF < 50%) was calculated before catheter ablation using baseline patients’ characteristics, 
while the MB-LATER scores (one point for Male gender, Bundle branch block or QRS >120 ms, LA diameter 
≥47 mm, AF Type (persistent AF), Early Recurrence <3 months) was calculated 3 months after ablation, when 
the data regarding early recurrences were available15,16.
Catheter ablation. AF catheter ablation was performed using a well-documented approach as previously 
described14. Briefly, patients presenting with AF at the beginning of the procedure were electrically cardioverted 
and ablation was performed during sinus rhythm (SR) (i.e., AF termination with ablation was not attempted). In 
all patients, circumferential LA ablation lines were placed around the antrum of the ipsilateral pulmonary veins 
(irrigated tip catheter, pre-selected tip temperature of 48 °C, and maximum power of 30–50 W). In patients with 
persistent AF, additional linear lesions were added at the LA roof, the basal posterior wall and the LA (mitral) 
isthmus. At the end of procedure, linear block was confirmed across the roof and the mitral isthmus. After cir-
cumferential line placement, voltage and pace mapping along the ablation lines were used to identify and close 
gaps. The isolation of all pulmonary veins with bidirectional block was verified with a multipolar circular map-
ping catheter and was defined as the procedural endpoint.
After ablation, class I and III antiarrhythmic drugs were routinely not reinitiated. Proton pump inhibitors were 
added for 4 weeks. According to the current guidelines, oral anticoagulation was prescribed for 3–6 months after 
catheter ablation and continued subsequently depending on stroke risk stratification using the CHA2DS2-VASc 
score thereafter5.
Follow-up. All patients were followed in the outpatient clinic after catheter ablation. During the follow-up 
period, 7-days Holter ECG recordings were performed (immediately, 3, 6 and 12 months after the ablation, then 
every 6 months). Additional resting ECGs and Holter ECG recordings were obtained when patients’ symptoms 
were suggestive of AF. Arrhythmia recurrences were defined as early (ERAF, occurring within 3 months after 
ablation) and late (LRAF, over 3 months period). If electrical or pharmacologic cardioversion and/or repeat pro-
cedure were needed, this was also considered as arrhythmia recurrence, i.e. a study endpoint.
statistical analysis. Data are presented as the mean/standard deviation for normally distributed or 
median/interquartile range (IQR) for skewed continuous variables and as proportions for categorical variables. 
Continuous variables were tested for normal distribution using the Kolmogorov–Smirnov test. The differences 
between continuous values were assessed using an unpaired two-tailed t-test for normally distributed continuous 
variables, a Mann–Whitney test for skewed variables, and a Chi-square test for nominal variables. The Kaplan–
Meier analysis was used to estimate the freedom of arrhythmia recurrences during follow-up period. The differ-
ences between low (0–1), intermediate (2–3) and high risk (4–5) accordingly to APPLE and MB-LATER scores 
were compared using log-rank analysis.
Cox regression analysis was used to identify factors associated with arrhythmia recurrences >3 months dur-
ing the whole follow-up. Multivariable analysis, which included variables with a p-value < 0.1 found on univari-
able analysis, was performed to identify independent predictors of recurrences.
Receiver operating characteristic (ROC) curves were generated for graphical illustration of APPLE, 
MB-LATER and modified scores’ performance in predicting rhythm outcome, with the area under the curve 
(AUC) being equivalent to the c-index for determining the predictive value for a score.
A p-value < 0.05 was considered as statistically significant. Statistical analyses were performed with IBM SPSS 
Statistics for Windows Version 25 (IBM Corp, Armonk, NY, USA).
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Results
The study population included 879 patients. Baseline characteristics are presented in Table 1. Median age was 
61 (IQR 54–68) years and 560 (64%) were males. The median observed follow-up time was 37 months with 95% 
CI [35;39]. ERAF and LRAF occurred in 45% and 64%, respectively. There were 89 (10%) and 98 (11%) patients 
receiving antiarrhythmic drugs at the discharge because of complicated ablation and/or operator’s decision and at 
3 months follow-up, respectively. Among them 69 (78%) and 81 (83%), respectively, had arrhythmia recurrences 
>3 months period (both p < 0.05).
There were 239 (27%) without any recurrences during follow-up, 78 (9%) with ERAF only, 248 (28%) with 
LRAF only, and 314 (36%) with both. Patients with LRAF were significantly older, had more often persistent 
AF, chronic heart failure, larger LA diameter and higher CHA2DS2-VASc, APPLE and MB-LATER scores than 
patients with sinus rhythm during follow-up (Table 1).
prediction of arrhythmia recurrences using clinical variables. On univariable Cox regression anal-
ysis, age, persistent AF type, diabetes mellitus, coronary artery disease, eGFR <60 ml/min/1.73 m², LA diame-
ter, and ERAF were significant time-dependent predictors of arrhythmia recurrences >3 months after ablation 
(Table 2).
On multivariable analysis, female sex (HR 1.329, 95% CI 1.093–1.616, p < 0.001), persistent AF type (HR 
1.425, 95% CI 1.192–1.703, p < 0.001), coronary artery disease (HR 1.454, 95% CI 1.148–1.842, p = 0.002), eGFR 
<60 ml/min/1.73 m² (HR 1.380, 95% CI 1.005–1.894, p = 0.046), LA diameter (HR 1.022, 95% CI 1.006–1.038, 
p = 0.006), and ERAF (HR 2.081, 95% CI 1.749–2.476, p < 0.001) remained significant predictors for LRAF, while 
bundle brunch block did not reach significance (HR 1.2, 95%CI 0.973–1.554, p = 0.084).
The APPLE (HR 1.385, 95% CI 1.276–1.505, p < 0.001) and MB-LATER (HR 1.326, 95% CI 1.239–1.419, 
p < 0.001) scores significantly predicted arrhythmia recurrences >3 months after ablation (Table 3). On ROC 
analyses, both scores demonstrated moderate predictive value for both scores: APPLE AUC 0.640 (95% CI 0.602–
0.677, p < 0.001) and MB-LATER AUC 0.654 (95% CI 0.616–0.691, p < 0.001, Table 3, Fig. 1).
Kaplan-Meier analysis. Using Kaplan-Meier curves, we analyzed the risk of late arrhythmia recurrences 
in patients accordingly to the low (0–1), intermediate (2–3) and high risk (4–5) accordingly to the APPLE and 
MB-LATER scores during follow-up. As expected, patients with lower risk (APPLE 0–1 and MB-LATER 0–1) had 
significantly better rhythm outcomes than patients with intermediate (APPLE and MB-LATER 2–3) or higher 
risk (APPLE and MB-LATER 4–5; log-rank <0.001, Figs 2–3).
There were 69%, 56%, 51%, and 43% probability for the arrhythmia freedom at 1-, 2-, 3- and 5-years for the 
low APPLE strata, while for the patients with intermediate APPLE score – 52%, 39%, 33%, and 22% for the same 
follow-up period (Fig. 2). Similarly, the arrhythmia freedom at 1-, 2-, 3- and 5-years for the low MB-LATER strata 
was 71%, 60%, 55%, and 46%, while patients with intermediate MB-LATER score remained at sinus rhythm at 
57%, 42%, 35%, and 28% (Fig. 3).
n (%) or median (IQR)
Total population 
n = 879
No recurrences 
n = 239
Only ERAF 
n = 78
Only LRAF 
n = 248
ERAF and 
LRAF n = 314 p-value
Age, years 61 (54–68) 60 (53–67) 60 (54–69) 62 (53–69) 63 (56–69) 0.034
Males 560 (64) 152 (64) 51 (65) 167 (67) 187 (60) 0.688
Persistent AF 339 (39) 58 (24) 27 (35) 97 (39) 157 (50) <0.001
BMI, kg/m2 28 (25–31) 28 (25–30) 28 (25–30) 28 (26–31) 28 (26–31) 0.438
BMI ≥30 kg/m² 290 (33) 70 (29) 20 (26) 89 (36) 111 (35) 0.056
Hypertension 649 (74) 171 (72) 57 (73) 178 (72) 243 (77) 0.701
Diabetes mellitus 154 (18) 34 (14) 10 (13) 44 (18) 66 (21) 0.129
Coronary artery disease 128 (15) 31 (13) 6 (8) 42 (17) 49 (16) 0.122
Chronic herat failure 61 (7) 6 (3) 4 (5) 18 (7) 33 (11) 0.008
Peripheral artery disease 87 (10) 18 (8) 8 (10) 30 (12) 31 (10) 0.110
eGFR, ml/min/1.73 m2 96 (79–118) 99 (83–119) 94 (76–121) 99 (77–120) 95 (79–114) 0.634
eGFR <60 ml/min/1.73 m2 64 (7) 9 (4) 4 (5) 24 (10) 27 (9) 0.006
LA diameter (AP), mm 42 (39–46) 41 (37–45) 42 (39–46) 43 (39–47) 43 (40–48) <0.001
EF, % 60 (55–65) 61 (57–65) 62 (56–66) 60 (55–65) 60 (53–65) 0.001
Bundle brunch block 60 (7) 14 (6) 2 (3) 19 (8) 25 (8) 0.089
CHA2DS2-VASc score 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–3) 0.004
APPLE score 1 (1–2) 1 (0–2) 1 (1–2) 2 (1–2) 2 (1–2) <0.001
MB-LATER score 2 (1–2) 1 (0–2) 2 (1–3) 1 (1–2) 2 (2–3) <0.001
Table 1. Baseline characteristics of the study population. Abbreviations: IQR – interquartile range, AF – atrial 
fibrillation, BMI – body mass index, eGFR – estimated glomerular filtration rate, LA – left atrial, AP – antero-
posterior, EF – ejection fraction.
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Discussion
To the best of our knowledge, the current study is the first one analyzing the time-dependent prognostic ability 
of APPLE and MB-LATER scores for the prediction of arrhythmia recurrences after first radiofrequency catheter 
ablation during long term follow-up. First, we found that both scores were associated with rhythm outcomes 
demonstrating moderate predictive ability. Furthermore, the rate of arrhythmia-free survival after catheter abla-
tion depends on the follow-up length and the scores strata. Finally, among clinical variables female sex, coronary 
artery disease, renal dysfunction, LA diameter, and ERAF were important factors associated with LRAF in a 
time-dependent manner.
Variables
Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Age, years 1.015 (1.006–1.024) 0.001 1.002 (0.992–1.012) 0.656
Females 1.178 (0.992–1.400) 0.062 1.329 (1.093–1.616) 0.004
Persistent AF 1.608 (1.361–1.901) <0.001 1.425 (1.192–1.703) <0.001
BMI ≥30, kg/m2 1.183 (0.995–1.407) 0.057 1.050 (0.867–1.271) 0.618
Hypertension 1.148 (0.947–1.391) 0.160
Diabetes mellitus 1.304 (1.058–1.607) 0.013 1.056 (0.847–1.315) 0.629
Coronary artery disease 1.469 (1.172–1.842) 0.001 1.454 (1.148–1.842) 0.002
Peripheral artery disease 1.266 (0.970–1.652) 0.083 1.157 (0.877–1.527) 0.302
eGFR <60 ml/min/1.73 m2 1.490 (1.117–1.988) 0.007 1.380 (1.005–1.894) 0.046
LA diameter, mm 1.034 (1.020–1.048) <0.001 1.022 (1.006–1.038) 0.006
EF, % 1.000 (0.999–1.001) 0.924
Bundle brunch block 1.251 (0.996–1.572) 0.054 1.230 (0.973–1.554) 0.084
ERAF 2.270 (1.920–2.684) <0.001 2.081 (1.749–2.476) <0.001
Table 2. Prediction of arrhythmia recurrences >3 months using clinical variables.
Scores HR (95% CI) AUC (95% CI) p-value
APPLE 1.385 (1.276–1.505) <0.001 0.640 (0.602–0.677) <0.001
MB-LATER 1.326 (1.239–1.419) <0.001 0.654 (0.616–0.691) <0.001
CHA2DS2-VASc 1.159 (1.097–1.225) <0.001 0.572 (0.534–0.611) <0.001
Table 3. Prediction of arrhythmia recurrences >3 months using scores.
Figure 1. ROC curves analysis for prediction of arrhythmia recurrences >3 months.
5Scientific RepoRts |          (2019) 9:7112  | https://doi.org/10.1038/s41598-019-43644-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
prediction of arrhythmia recurrences. Despite advanced mapping, ablation catheters and techniques, 
arrhythmia recurrences still remain a common issue after catheter ablation. Therefore, there is a considerable 
clinical interest to predict the risk of recurrences occurrence already before procedure. Despite the availability 
Figure 2. (A) Prediction of arrhythmia recurrences >3 months using APPLE score low, intermediate and high 
strata during follow-up (B). Probability for AF freedom at 1-, 2-, 3-, and 5-years accordingly to the APPLE score 
strata. *small sample size (<5 patients).
Figure 3. (A) Prediction of arrhythmia recurrences >3 months using MB-LATER score low, intermediate and 
high strata during follow-up (B). Probability for AF freedom at 1-, 2-, 3-, and 5-years accordingly to the MB-
LATER score strata.
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of multiple rhythm prediction scores, the prediction of arrhythmia recurrences remains challenging and not in a 
wide usage in a daily clinical routine.
During the recent years, several studies demonstrated the impact of diverse clinical scores on recurrence 
prediction. First, the thromboembolic risk predicting CHADS2 and CHA2DS2-VASc scores showed relatively 
modest prediction for arrhythmia recurrences7,8. Later, several specific rhythm outcomes prediction scores as 
ALARMEC, BASE-AF2, CAAP-AF, ATLAS and LAGO had been introduced6,9–12. However, the results of these 
studies are partly difficult to interpret because of some non-standardized definitions, relatively small study pop-
ulations and short follow-up period. However, the direct comparison of the scores is difficult because of different 
cohort sizes and different AF ablation protocols. Also, only few scores had such a quality criterion as the external 
validation. In AF patients undergoing radiofrequency ablation only APPLE and MB-LATER scores were vali-
dated in several external cohorts13.
The APPLE and MB-LATER scores were both introduced as rhythm outcomes predicting scores. While the 
APPLE score predicted arrhythmia recurrences within one year in patients undergoing first and repeat abla-
tion14,17, the MB-LATER score had been developed for the prediction of arrhythmia recurrences over 12 months 
in patients with arrhythmia-free survival within first year15.
In current study, we found that several clinical factors, including persistent AF type, LA diameter and ERAF 
were significantly associated with arrhythmia recurrences during long-term follow-up. These results are in line 
with our previous study and recent meta-analysis18,19 Importantly, persistent AF type was included into both 
APPLE and MB-LATER scores and remained significant time-dependent predictor for the arrhythmia recur-
rences. This could be explained by higher prevalence of low voltage areas in patients with persistent AF type. 
However, this can be only speculated as a decade ago an electro-anatomical mapping was not routinely performed 
in the study cohort.
eRAF as a time-dependent predictor of arrhythmia recurrences. It had been already demonstrated 
that patients with ERAF are more likely to suffer from long-term arrhythmia recurrences20. Nevertheless, in more 
than half of patients with ERAF a delayed cure during subsequent follow-up is possible21. Hence, a blanking 
period of 3 months is considered as meaningful to avoid unnecessary repeat procedures. Recent studies found 
that up to 67% of patients with ERAF suffered LRAF during longer follow-up22, and a recurrence free-rate in 
persistent AF after single procedure was only in 28%23. These findings are in line with our current results. We 
found significant differences in clinical profiles between patients without recurrences, with ERAF or LRAF only, 
and with both recurrences. Patients suffering LRAF and ERAF/LRAF were significantly older, had more often 
persistent AF, larger LA diameter and higher APPLE and MB-LATER scores than patients without recurrences 
at all or only with ERAF. Furthermore, we demonstrate that the arrhythmia-free survival changed significantly 
during follow-up period reaching 43% and 22% for low and intermediate APPLE or 46% and 28% for low and 
intermediate MB-LATER strata at 5-years milestone.
In our recent study, the ERAF demonstrated the best association with LRAF in a contemporary AF ablation 
cohort and in the retrospective validation subgroup from The Leipzig Heart Center AF Ablation Registry16. 
Also, we found that patients with ERAF had almost 4-fold risk for LRAF occurrence during follow-up19. This 
had been also confirmed by a meta-analysis18 and in our current study. However, ERAF is not available at 
baseline, and MB-LATER cannot be calculated before catheter ablation – in contrast to the APPLE score. 
Nevertheless, a relatively moderate predictive value of both scores in ROC analysis indicates that a robust 
rhythm outcome predicting score still remains a clinical unmet need. The role of other variables – especially 
imaging, biomarkers, electro-anatomical features – should be analysed building a novel or improving previous 
rhythm outcome scores.
study limitations. This study is limited by its observational, retrospective design in a single-center cohort. 
First, the majority of the patients were not monitored by loop recorders; asymptomatic episodes of silent AF 
could have been missed. Second, there were only patients undergoing first radiofrequency AF catheter ablation. 
The results could differ in patients with repeated procedures or with ablation using other sources. Third, the 
electro-anatomical mapping data were not routinely performed in the whole study cohort. Furthermore, the 
data of obstructive sleep apnoea syndrome, thyroid disease and sick sinus syndrome, which may have an impact 
on AF progression and occurrence of arrhythmia recurrences after catheter ablation, were not available in this 
study. Also, because of very low patient numbers with high risk accordingly to the APPLE score (e.g. APPLE 
4–5) including only 16 patients, a robust statistical analysis for this subgroup was not possible. The prediction 
of arrhythmia recurrences for these patients should be evaluated in larger prospective studies including larger 
numbers of such sub-cohort. Finally, whether APPLE and MB-LATER score have enough strength to be consid-
ered for explaining the patients the expected outcome of the procedure, and therefore to balance advantages and 
disadvantages when considering a patient for AF ablation, could be answered only in controlled randomized trials 
addressing this issue.
Conclusions
APPLE and MB-LATER scores were useful for the time-dependent prediction of arrhythmia recurrences 
in patients undergoing first AF catheter ablation. The rate of arrhythmia-free survival after catheter ablation 
depends on the follow-up length and the scores strata.
Data Availability
All data generated or analyzed during this study are included in this published article.
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